The University of Chicago Header Logo

Connection

Mark Ratain to Neoplasms

Back to Details
This is a "connection" page, showing publications Mark Ratain has written about Neoplasms.
Mark Ratain
Connection Strength
12.849
Neoplasms
  1. Special designations and the US Food and Drug Administration's "dual mandate". J Natl Cancer Inst. 2024 02 08; 116(2):177-179.
    View in: PubMed
    Score: 0.283
  2. Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
    View in: PubMed
    Score: 0.281
  3. Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest? Nat Biotechnol. 2023 11; 41(11):1517-1519.
    View in: PubMed
    Score: 0.278
  4. Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy. Ann Oncol. 2023 08; 34(8):638-644.
    View in: PubMed
    Score: 0.270
  5. US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action? J Clin Oncol. 2023 05 10; 41(14):2488-2492.
    View in: PubMed
    Score: 0.265
  6. An Expanded Role for IRBs in the Oversight of Research Biopsies. Ethics Hum Res. 2022 Sep; 44(5):32-41.
    View in: PubMed
    Score: 0.256
  7. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? J Clin Oncol. 2021 11 01; 39(31):3423-3426.
    View in: PubMed
    Score: 0.240
  8. Introduction by the Guest Editors. Cancer J. 2020 Jul/Aug; 26(4):279-280.
    View in: PubMed
    Score: 0.221
  9. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. Clin Pharmacol Ther. 2020 09; 108(3):487-493.
    View in: PubMed
    Score: 0.219
  10. A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting". JAMA Oncol. 2019 12 01; 5(12):1691-1692.
    View in: PubMed
    Score: 0.212
  11. Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. J Clin Oncol. 2019 09 10; 37(26):2368-2377.
    View in: PubMed
    Score: 0.207
  12. The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost. Clin Cancer Res. 2019 02 15; 25(4):1136-1138.
    View in: PubMed
    Score: 0.198
  13. Drug-Drug Interactions With Oral Antineoplastic Agents. JAMA Oncol. 2017 06 01; 3(6):736-738.
    View in: PubMed
    Score: 0.178
  14. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 08; 35(4):471-477.
    View in: PubMed
    Score: 0.174
  15. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74.
    View in: PubMed
    Score: 0.161
  16. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov 15; 21(22):5057-63.
    View in: PubMed
    Score: 0.160
  17. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10.
    View in: PubMed
    Score: 0.154
  18. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7.
    View in: PubMed
    Score: 0.147
  19. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
    View in: PubMed
    Score: 0.145
  20. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2013 Mar; 93(3):242-4.
    View in: PubMed
    Score: 0.131
  21. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
    View in: PubMed
    Score: 0.130
  22. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point. Cancer Res. 2012 Oct 15; 72(20):5145-9; discussion 5150.
    View in: PubMed
    Score: 0.128
  23. Why RECIST works and why it should stay--reply to counterpoint. Cancer Res. 2012 Oct 15; 72(20):5158.
    View in: PubMed
    Score: 0.128
  24. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
    View in: PubMed
    Score: 0.128
  25. Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity? Clin Cancer Res. 2012 Aug 15; 18(16):4219-21.
    View in: PubMed
    Score: 0.127
  26. Importance of food effects for oral oncology drugs. Clin Adv Hematol Oncol. 2012 Jun; 10(6):397-8.
    View in: PubMed
    Score: 0.126
  27. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012 Apr; 6(2):251-9.
    View in: PubMed
    Score: 0.123
  28. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
    View in: PubMed
    Score: 0.116
  29. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.116
  30. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
    View in: PubMed
    Score: 0.112
  31. Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res. 2010 Nov 01; 16(21):5296-302.
    View in: PubMed
    Score: 0.112
  32. Bar the windows but open the door to randomization. J Clin Oncol. 2010 Jul 01; 28(19):3104-6.
    View in: PubMed
    Score: 0.110
  33. Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr; 6(4):563-85.
    View in: PubMed
    Score: 0.108
  34. Individualizing dosing of irinotecan. Clin Cancer Res. 2010 Jan 15; 16(2):371-2.
    View in: PubMed
    Score: 0.107
  35. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.105
  36. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J. 2009 Sep-Oct; 15(5):426-30.
    View in: PubMed
    Score: 0.104
  37. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009 Apr 10; 27(11):1800-5.
    View in: PubMed
    Score: 0.101
  38. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
    View in: PubMed
    Score: 0.100
  39. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer. 2009 Jan; 45(2):275-80.
    View in: PubMed
    Score: 0.099
  40. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
    View in: PubMed
    Score: 0.096
  41. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6545-8.
    View in: PubMed
    Score: 0.092
  42. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60.
    View in: PubMed
    Score: 0.090
  43. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007 Feb 01; 13(3):781-2.
    View in: PubMed
    Score: 0.087
  44. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006 Jul; 62(1):35-46.
    View in: PubMed
    Score: 0.084
  45. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
    View in: PubMed
    Score: 0.083
  46. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol. 2006 May 10; 24(14):2151-7.
    View in: PubMed
    Score: 0.083
  47. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer. 2006 05; 6(5):409-14.
    View in: PubMed
    Score: 0.083
  48. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.083
  49. Phase II oncology trials: let's be positive. Clin Cancer Res. 2005 Aug 15; 11(16):5661-2.
    View in: PubMed
    Score: 0.079
  50. Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs. Clin Pharmacol Ther. 2025 Oct; 118(4):772-777.
    View in: PubMed
    Score: 0.078
  51. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65.
    View in: PubMed
    Score: 0.077
  52. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7.
    View in: PubMed
    Score: 0.075
  53. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004 Dec 15; 10(24):8325-31.
    View in: PubMed
    Score: 0.075
  54. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58.
    View in: PubMed
    Score: 0.075
  55. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
    View in: PubMed
    Score: 0.075
  56. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 01; 10(21):7244-51.
    View in: PubMed
    Score: 0.075
  57. Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access. J Natl Compr Canc Netw. 2024 08; 22(6):435-436.
    View in: PubMed
    Score: 0.073
  58. A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Nov; 54(5):377-84.
    View in: PubMed
    Score: 0.073
  59. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
    View in: PubMed
    Score: 0.073
  60. Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer. Clin Pharmacol Ther. 2024 Sep; 116(3):508-510.
    View in: PubMed
    Score: 0.072
  61. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec; 14(12):1783-90.
    View in: PubMed
    Score: 0.070
  62. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003 Sep 29; 22(42):6621-8.
    View in: PubMed
    Score: 0.069
  63. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003 Aug; 13(8):517-23.
    View in: PubMed
    Score: 0.068
  64. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol. 2003 Jul 15; 21(14):2633-5.
    View in: PubMed
    Score: 0.068
  65. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7.
    View in: PubMed
    Score: 0.068
  66. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):52-5.
    View in: PubMed
    Score: 0.067
  67. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. Med Oncol. 2003; 20(1):7-12.
    View in: PubMed
    Score: 0.066
  68. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
    View in: PubMed
    Score: 0.065
  69. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60.
    View in: PubMed
    Score: 0.064
  70. Endostatin: are the 2 years up yet? J Clin Oncol. 2002 Sep 15; 20(18):3758-60.
    View in: PubMed
    Score: 0.064
  71. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.064
  72. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
    View in: PubMed
    Score: 0.063
  73. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022 08; 40(4):762-772.
    View in: PubMed
    Score: 0.063
  74. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res. 2002 Apr; 8(4):1042-8.
    View in: PubMed
    Score: 0.062
  75. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer. 2002 Mar; 38(5):639-44.
    View in: PubMed
    Score: 0.062
  76. Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Br J Cancer. 2002 Feb 12; 86(4):534-9.
    View in: PubMed
    Score: 0.062
  77. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
    View in: PubMed
    Score: 0.061
  78. Pharmacogenetics in cancer treatment. Annu Rev Med. 2003; 54:437-52.
    View in: PubMed
    Score: 0.061
  79. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol. 2001 Dec; 12(12):1743-7.
    View in: PubMed
    Score: 0.061
  80. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274.
    View in: PubMed
    Score: 0.060
  81. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289.
    View in: PubMed
    Score: 0.060
  82. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. Oncologist. 2021 11; 26(11):e2042-e2052.
    View in: PubMed
    Score: 0.060
  83. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
    View in: PubMed
    Score: 0.060
  84. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.059
  85. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
    View in: PubMed
    Score: 0.058
  86. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
    View in: PubMed
    Score: 0.058
  87. Gazing into a crystal ball-cancer therapy in the post-genomic era. Nat Med. 2001 Mar; 7(3):283-5.
    View in: PubMed
    Score: 0.058
  88. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. J Clin Oncol. 2021 03 20; 39(9):950-955.
    View in: PubMed
    Score: 0.058
  89. Elimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab Dispos. 2001 Feb; 29(2):96-9.
    View in: PubMed
    Score: 0.057
  90. Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change. JAMA Oncol. 2021 01 01; 7(1):25-26.
    View in: PubMed
    Score: 0.057
  91. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
    View in: PubMed
    Score: 0.055
  92. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul; 18(14):2780-7.
    View in: PubMed
    Score: 0.055
  93. Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000 May-Jun; 22(3):6-14.
    View in: PubMed
    Score: 0.055
  94. Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16.
    View in: PubMed
    Score: 0.054
  95. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
    View in: PubMed
    Score: 0.052
  96. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer. 1999 Aug 01; 86(3):528-32.
    View in: PubMed
    Score: 0.052
  97. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9.
    View in: PubMed
    Score: 0.049
  98. Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998 Sep; 34(10):1493-9.
    View in: PubMed
    Score: 0.049
  99. Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491.
    View in: PubMed
    Score: 0.048
  100. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.048
  101. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744.
    View in: PubMed
    Score: 0.048
  102. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.048
  103. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050.
    View in: PubMed
    Score: 0.047
  104. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.047
  105. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7.
    View in: PubMed
    Score: 0.046
  106. Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9.
    View in: PubMed
    Score: 0.045
  107. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30.
    View in: PubMed
    Score: 0.045
  108. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997 Apr; 15(4):1502-10.
    View in: PubMed
    Score: 0.044
  109. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
    View in: PubMed
    Score: 0.043
  110. Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov; 8(6):525-34.
    View in: PubMed
    Score: 0.043
  111. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484.
    View in: PubMed
    Score: 0.043
  112. Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose. J Clin Oncol. 1996 Sep; 14(9):2622-3.
    View in: PubMed
    Score: 0.042
  113. Data modifications to phase I study of suramin. J Clin Oncol. 1996 Sep; 14(9):2623-4.
    View in: PubMed
    Score: 0.042
  114. Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. Cancer. 1996 Jun 01; 77(11):2308-12.
    View in: PubMed
    Score: 0.042
  115. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. Clin Transl Sci. 2016 Feb; 9(1):43-50.
    View in: PubMed
    Score: 0.041
  116. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol. 1995 Sep; 13(9):2196-207.
    View in: PubMed
    Score: 0.039
  117. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
    View in: PubMed
    Score: 0.039
  118. Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). J Natl Cancer Inst. 2015 Oct; 107(10).
    View in: PubMed
    Score: 0.039
  119. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb; 16(1):54-9.
    View in: PubMed
    Score: 0.038
  120. User beware: we need more science and less art when measuring financial toxicity in oncology. J Clin Oncol. 2015 Apr 20; 33(12):1414-5.
    View in: PubMed
    Score: 0.038
  121. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994 Oct 01; 74(7):1965-73.
    View in: PubMed
    Score: 0.037
  122. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73.
    View in: PubMed
    Score: 0.036
  123. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014 Oct 15; 120(20):3245-53.
    View in: PubMed
    Score: 0.036
  124. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther. 2014 Apr; 95(4):361-4.
    View in: PubMed
    Score: 0.036
  125. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
    View in: PubMed
    Score: 0.036
  126. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2205-14.
    View in: PubMed
    Score: 0.036
  127. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
    View in: PubMed
    Score: 0.035
  128. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
    View in: PubMed
    Score: 0.035
  129. Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol. 1994; 34 Suppl:S64-8.
    View in: PubMed
    Score: 0.035
  130. Tumour heterogeneity in the clinic. Nature. 2013 Sep 19; 501(7467):355-64.
    View in: PubMed
    Score: 0.034
  131. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
    View in: PubMed
    Score: 0.034
  132. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
    View in: PubMed
    Score: 0.034
  133. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.033
  134. A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer. 1993 Apr 01; 71(7):2371-6.
    View in: PubMed
    Score: 0.033
  135. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. Cancer Res. 1993 Mar 15; 53(6):1293-6.
    View in: PubMed
    Score: 0.033
  136. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv. 1993; 17:51-78.
    View in: PubMed
    Score: 0.033
  137. Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52.
    View in: PubMed
    Score: 0.033
  138. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33.
    View in: PubMed
    Score: 0.033
  139. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32.
    View in: PubMed
    Score: 0.030
  140. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6.
    View in: PubMed
    Score: 0.030
  141. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
    View in: PubMed
    Score: 0.030
  142. Current dilemmas in carboplatin dosing. Clin Adv Hematol Oncol. 2011 Mar; 9(3):237-8.
    View in: PubMed
    Score: 0.029
  143. Merrill Jon Egorin, MD, 1948-2010. Clin Pharmacol Ther. 2011 Feb; 89(2):163-5.
    View in: PubMed
    Score: 0.029
  144. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.028
  145. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53.
    View in: PubMed
    Score: 0.028
  146. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
    View in: PubMed
    Score: 0.027
  147. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9.
    View in: PubMed
    Score: 0.027
  148. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
    View in: PubMed
    Score: 0.027
  149. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 2009 Jul; 10(7):1139-46.
    View in: PubMed
    Score: 0.026
  150. Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther. 2009 Feb; 85(2):134-5.
    View in: PubMed
    Score: 0.025
  151. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1):42-55.
    View in: PubMed
    Score: 0.025
  152. Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
    View in: PubMed
    Score: 0.025
  153. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402.
    View in: PubMed
    Score: 0.024
  154. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8.
    View in: PubMed
    Score: 0.023
  155. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007 Aug 10; 25(23):3488-94.
    View in: PubMed
    Score: 0.023
  156. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 01; 13(11):3302-11.
    View in: PubMed
    Score: 0.022
  157. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol. 2007 Feb 10; 25(5):548-54.
    View in: PubMed
    Score: 0.022
  158. Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res. 1986 Sep; 46(9):4827-30.
    View in: PubMed
    Score: 0.021
  159. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
    View in: PubMed
    Score: 0.021
  160. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug; 27(8):432-7.
    View in: PubMed
    Score: 0.021
  161. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005 Jun; 5(6):447-58.
    View in: PubMed
    Score: 0.019
  162. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
    View in: PubMed
    Score: 0.019
  163. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004 Nov 15; 22(22):4442-5.
    View in: PubMed
    Score: 0.019
  164. The tyranny of non-inferiority trials. Lancet Oncol. 2024 Oct; 25(10):e520-e525.
    View in: PubMed
    Score: 0.019
  165. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.
    View in: PubMed
    Score: 0.018
  166. Finding the right dose. Clin Adv Hematol Oncol. 2003 Sep; 1(9):517-8, 531.
    View in: PubMed
    Score: 0.017
  167. Anticancer drug discovery and development throughout the world. J Clin Oncol. 2002 Sep 15; 20(18 Suppl):47S-59S.
    View in: PubMed
    Score: 0.016
  168. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002 Aug; 50(2):121-6.
    View in: PubMed
    Score: 0.016
  169. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2002 May; 8(5):1314; author reply 1315-6.
    View in: PubMed
    Score: 0.016
  170. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7.
    View in: PubMed
    Score: 0.015
  171. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84.
    View in: PubMed
    Score: 0.014
  172. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999 Aug 04; 91(15):1281-7.
    View in: PubMed
    Score: 0.013
  173. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol. 1999; 43(5):385-8.
    View in: PubMed
    Score: 0.012
  174. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
    View in: PubMed
    Score: 0.012
  175. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
    View in: PubMed
    Score: 0.012
  176. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol. 1996 Jul; 14(7):2012-9.
    View in: PubMed
    Score: 0.010
  177. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7.
    View in: PubMed
    Score: 0.010
  178. Pushing the envelope: informed consent in phase I trials. Ann Oncol. 1995 Apr; 6(4):321-3.
    View in: PubMed
    Score: 0.010
  179. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst. 1994 Nov 16; 86(22):1685-93.
    View in: PubMed
    Score: 0.009
  180. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72.
    View in: PubMed
    Score: 0.009
  181. Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14.
    View in: PubMed
    Score: 0.009
  182. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther. 1993 Oct; 54(4):421-9.
    View in: PubMed
    Score: 0.009
  183. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst. 1993 Aug 18; 85(16):1319-26.
    View in: PubMed
    Score: 0.009
  184. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993 Feb 03; 85(3):217-23.
    View in: PubMed
    Score: 0.008
  185. Individualizing dosing of cancer chemotherapy. Semin Oncol. 1993 Feb; 20(1):30-42.
    View in: PubMed
    Score: 0.008
  186. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.
    View in: PubMed
    Score: 0.008
  187. Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol. 1992 Aug; 19(4 Suppl 11):8-13.
    View in: PubMed
    Score: 0.008
  188. Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73.
    View in: PubMed
    Score: 0.007
  189. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
    View in: PubMed
    Score: 0.005
  190. Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treat Rep. 1986 Sep; 70(9):1081-4.
    View in: PubMed
    Score: 0.005
  191. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006 Apr 20; 24(12):1846-51.
    View in: PubMed
    Score: 0.005
  192. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
    View in: PubMed
    Score: 0.004
  193. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9.
    View in: PubMed
    Score: 0.003
  194. Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997 Jun 01; 126(11):892-7.
    View in: PubMed
    Score: 0.003
  195. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Cancer Res. 1989 Mar 01; 49(5):1318-21.
    View in: PubMed
    Score: 0.002
  196. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. J Clin Oncol. 1988 Jul; 6(7):1192-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.